| Code | CSB-RA723415MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody HBM-1007, targeting NT5E (ecto-5'-nucleotidase), also known as CD73. NT5E is an ectoenzyme that catalyzes the conversion of extracellular adenosine monophosphate (AMP) to adenosine, a potent immunosuppressive molecule in the tumor microenvironment. By generating adenosine, NT5E plays a critical role in immune evasion mechanisms employed by various cancers, suppressing T cell and NK cell activity while promoting regulatory T cell function. Elevated NT5E expression has been associated with poor prognosis in multiple malignancies, including triple-negative breast cancer, melanoma, ovarian cancer, and colorectal cancer.
HBM-1007 represents a therapeutic antibody designed to block NT5E enzymatic activity and restore anti-tumor immune responses. This biosimilar provides researchers with a valuable tool for investigating adenosine-mediated immunosuppression, studying checkpoint inhibitor resistance mechanisms, and exploring combination immunotherapy strategies. The antibody enables detailed examination of NT5E function in tumor biology, immune regulation, and potential therapeutic interventions targeting the adenosine pathway in cancer research.
There are currently no reviews for this product.